Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
11.36
+0.42 (3.84%)
Oct 19, 2026, 12:40 PM EDT - Market open
Sutro Biopharma Revenue
Sutro Biopharma had revenue of $9.84M in the quarter ending June 30, 2026, a decrease of -84.57%. This brings the company's total for the last twelve months to $45.70M, down -56.25% year-over-year. In the year 2025, Sutro Biopharma had annual revenue of $102.48M with 65.18% growth. That makes Sutro Biopharma the 28,580th largest company in the world by revenue and 3,845th in the United States.
Revenue (ttm)
$45.70M
Revenue Growth
-56.25%
P/S Ratio
3.97
Revenue / Employee
$357,047
Employees
128
Market Cap
188.36M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 102.48M | 40.44M | 65.18% |
| Dec 31, 2024 | 62.04M | -91.69M | -59.64% |
| Dec 31, 2023 | 153.73M | 85.96M | 126.84% |
| Dec 31, 2022 | 67.77M | 5.89M | 9.52% |
| Dec 31, 2021 | 61.88M | 19.16M | 44.84% |
| Dec 31, 2020 | 42.72M | -14.00K | -0.03% |
| Dec 31, 2019 | 42.74M | 4.32M | 11.24% |
| Dec 31, 2018 | 38.42M | -13.32M | -25.75% |
| Dec 31, 2017 | 51.74M | -7.99M | -13.38% |
| Dec 31, 2016 | 59.73M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Compugen | 74.00M |
| Invivyd | 58.37M |
| ProQR Therapeutics | 21.05M |
| Alpha Cognition | 15.26M |
| Evommune | 10.00M |
| Cartesian Therapeutics | 1.48M |
STRO News
- 20 days ago - Sutro Biopharma appoints Donigian as SVP, Business Development - TheFly
- 20 days ago - Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development - GlobeNewsWire
- 4 weeks ago - Sutro Biopharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 2 months ago - Sutro Biopharma reports Q2 EPS ($2.33), consensus ($2.27) - TheFly
- 2 months ago - H.C. Wainwright calls Sutro drop ‘an overreaction’ to limited STRO-004 data - TheFly
- 2 months ago - Sutro Biopharma price target lowered to $34 from $41 at Citizens - TheFly
- 2 months ago - Sutro Biopharma Slides: Corporate presentation - Filings
- 2 months ago - Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study - GlobeNewsWire